Engineered Phage Cocktail for Drug-Resistant Tuberculosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The resurgence of multi-drug resistant Mycobacterium tuberculosis strains and the challenges of lengthy treatment durations with adverse side effects have hindered effective tuberculosis therapy, necessitating new therapeutic strategies.

Innovation Solution

A combination pharmaceutical composition comprising five or more genetically engineered bacteriophages and a pharmaceutically acceptable carrier is administered to treat, reduce, or prevent Mycobacterium tuberculosis infections, including antibiotic-resistant strains, by targeting various lineages of the bacteria.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional antibiotics are used to treat tuberculosis, then treatment effectiveness is initially good, but drug resistance develops over time leading to treatment failure

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddrug resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines multiple bacteriophages (at least five different phages) into a single pharmaceutical composition to treat tuberculosis. This combination approach allows the phages to target different bacterial populations simultaneously, reducing the likelihood of resistance development while maintaining treatment effectiveness against both susceptible and resistant M. tuberculosis strains.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent uses genetically engineered bacteriophages with modified parameters compared to wild-type phages. The phages are engineered to have enhanced stability, altered host range, or improved lytic efficiency, allowing them to effectively infect and kill M. tuberculosis strains that have developed resistance to traditional antibiotics.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If lengthy antibiotic treatment regimens are used, then treatment completeness increases, but patient compliance decreases due to adverse side effects and treatment duration

Engineering Contradiction:

Improvetreatment completenessVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The bacteriophage-based treatment is designed to act more rapidly than traditional antibiotics by directly infecting and lysing bacterial cells. This mechanism allows for potentially shorter treatment durations while achieving complete eradication of the infection, thereby improving patient compliance without sacrificing treatment completeness.

Inventive Principle:

Principle #21Skipping (Rushing through)

Solution Approach 2:

The bacteriophages are self-replicating agents that multiply inside bacterial cells and automatically spread to infect more bacteria. This self-propagating mechanism eliminates the need for continuous external administration and reduces the burden on patients, potentially allowing for shorter treatment courses while maintaining high treatment completeness.

Inventive Principle:

Principle #25Self-service

3Adaptability or versatility

If new therapeutic strategies are developed, then treatment options for drug-resistant strains improve, but treatment cost increases

Engineering Contradiction:

Improvetreatment options for resistant strainsVSAvoidtreatment cost

Core Design Contradiction:

Adaptability or versatilityVSQuantity of substance

Solution Approach 1:

The bacteriophage pharmaceutical composition is designed as a disposable treatment where the phages are administered to infect and kill bacteria. The phages naturally degrade after use and are replaced by subsequent doses if needed. This approach avoids the need for expensive long-term maintenance therapies and provides cost-effective treatment for drug-resistant tuberculosis strains.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The phage cocktail efficiently kills all tested M. tuberculosis strains, reducing treatment duration and addressing antibiotic resistance, with potential for shorter treatment courses and broader host range efficacy.

Implementation Method 1

Bacteriophages are viruses that infect and kill bacteria. The phage cocktail efficiently kills all tested M. tuberculosis strains

Methodology Applied

Scientific EffectBacteriophage infection and lysis:

Data Source

PatentUS12589127B2Bacteriophages for treatment of tuberculosis

Publication Date: 2026.03.31 UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

AI summary

Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.